QIAGEN Introduces QIAsymphony Sample Processing Option to GeneReader NGS Workflow for Non U.S. Customers

Page 1
QIAGEN Introduces QIAsymphony Sample Processing Option to GeneReader NGS Workflow for Non U.S. Customers

HILDEN, Germany, October 5, 2016 /PRNewswire/ --

     QIAsymphony SP front-end adds higher sample throughput and additional flexibility to

                                GeneReader NGS System  

    QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the launch
outside of the United States of its QIAsymphony SP instrument as a front-end option for
sample processing for the GeneReader NGS System*, adding highly automated, higher
throughput sample volumes and high flexibility to the world's first complete Sample to
Insight solution for next-generation sequencing (NGS). The GeneReader NGS workflow can now
integrate seamlessly with QIAsymphony SP, enabling laboratories outside the United States
to perform sample processing of different sample types simultaneously with continuous
loading, random access and greater speed for demanding environments.

    "Where available, the GeneReader NGS System is gaining adoption as a complete,
user-friendly solution for next-generation sequencing, and QIAsymphony SP adds a reliable
front-end to the GeneReader NGS System for higher throughput workflows. We are currently
marketing the GeneReader NGS workflow outside the United States. As an alternative to the
QIAcube, which automates lower throughput sample processing, QIAsymphony SP handles
varying sample volumes and types simply and efficiently for GeneReader NGS users," said
Jonathan Arnold, QIAGEN's Oncology Franchise Business Leader.

    Click here
[https://www.qiagen.com/about-us/press-releases/pressreleaseview?ID=%7bAB23227B-C4EC-4081-96A5-C5F5D2E61269%7d&lang=en ]
for full press release

    https://www.qiagen.com/about-us/press-releases/pressreleaseview?ID=
{AB23227B-C4EC-4081-96A5-C5F5D2E61269}&lang=en
[https://www.qiagen.com/about-us/press-releases/pressreleaseview?ID=%7bAB23227B-C4EC-4081-96A5-C5F5D2E61269%7d&lang=en ]

       
         
        Contacts: 

        Public Relations: 
        Dr. Thomas Theuringer 
        Senior Director Public Relations 
        +49-2103-29-11826 

        Email: pr@qiagen.com 
        http://www.twitter.com/qiagen 
        https://www.facebook.com/QIAGEN 
        pr.qiagen.com [https://www.qiagen.com/de/about-us ] 

        Investor Relations: 
        John Gilardi 
        Vice President Corporate Communications and Investor Relations 
        +49-2103-29-11711 

        Email: ir@qiagen.com 
        ir.qiagen.com [http://www.qiagen.com/About-Us/Investors ] 

     

QIAGEN N.V.